Expanded Access for ACE-011
NCT03724227 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2020-07-17
Summary
This is an expanded access program (EAP) for eligible participants designed to provide access to ACE-011.
Conditions
Interventions
- DRUG
-
ACE-011
ACE-011 will be administered subcutaneous injection
Sponsors & Collaborators
-
Celgene
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes
NCT00384956 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)
NCT01168921 ·Status: COMPLETED ·Phase: PHASE2
-
Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation
NCT02196857 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes
NCT02240706 ·Status: TERMINATED ·Phase: PHASE2
-
Expanded Access to Ziftomenib
NCT05738538 ·Status: AVAILABLE
-
Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes
NCT02281084 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia
NCT01772420 ·Status: COMPLETED ·Phase: PHASE2
-
ALL Backbone in AYAs
NCT07227584 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
NCT02494258 ·Status: COMPLETED ·Phase: PHASE2
-
Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome
NCT00003984 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT05673057 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
CPX-351 in Higher Risk Myelodysplastic Syndromes
NCT04273802 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
NCT05581030 ·Status: RECRUITING ·Phase: PHASE1
-
A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351
NCT03555955 ·Status: COMPLETED ·Phase: PHASE1
-
CPX-351 Therapy for MDS After Hypomethylating Agent Failure
NCT03957876 ·Status: TERMINATED ·Phase: PHASE2
-
AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™
NCT00058747 ·Status: TERMINATED ·Phase: PHASE2
-
A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Oral Azacitidine in Japanese Patients With Myelodysplastic Syndromes
NCT01571648 ·Status: COMPLETED ·Phase: PHASE1
-
An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes
NCT01381809 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes
NCT00045786 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Azacitidine in Myelodysplastic Syndrome (MDS) Associated to Systemic Auto-immune and Inflammatory Disorders
NCT02985190 ·Status: COMPLETED ·Phase: PHASE2
-
MCLA-117 in Acute Myelogenous Leukemia
NCT03038230 ·Status: TERMINATED ·Phase: PHASE1
-
Peptide-drug-conjugates for Personalized, Targeted Therapy of Chronic Lymphocytic Leukemia
NCT02828774 ·Status: UNKNOWN
-
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis
NCT00001586 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)
NCT07053059 ·Status: RECRUITING ·Phase: PHASE2